NCT00925015 2018-08-15Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)Merck Sharp & Dohme LLCPhase 1 Completed20 enrolled 30 charts
NCT00614393 2018-08-08Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)Merck Sharp & Dohme LLCPhase 2 Completed558 enrolled 17 charts